Bragar Eagel & Squire Files Class Action Against Alexandria for 2025 Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 17 2026
0mins
Should l Buy ARE?
Source: Globenewswire
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Alexandria Real Estate Equities in the Central District of California on behalf of investors who purchased securities between January 27 and October 27, 2025, alleging the company made materially false and misleading statements during this period.
- Allegation Details: The complaint claims that Alexandria concealed significant adverse facts regarding the true state of its Long Island City property, particularly lacking a reasonable basis for its confidence in the leasing value related to its Megacampus™ strategy, misleading investors about the company's prospects.
- Investor Rights: Affected investors must apply by January 26, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering free consultations to assist investors in understanding their rights and options.
- Law Firm Overview: Bragar Eagel & Squire is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, with a broad nationwide practice.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 48.010
Low
41.00
Averages
56.85
High
67.00
Current: 48.010
Low
41.00
Averages
56.85
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Market Performance: Alexandria Real Estate Equities has cut its target price for the stock from $65 to $52, indicating a shift in market expectations.
Outperformance: The company has been noted for its performance in the market, suggesting it has been outperforming its peers prior to the target price adjustment.
See More
- Reasons for Sell-Off: Healthcare stocks are experiencing a sell-off due to turbulence in the Middle East, despite typically being resilient during global uncertainties; the sector has been weighed down for months by Medicaid cuts and pharmaceutical tariffs, impacting investor confidence.
- Pfizer's Outlook: Pfizer (PFE) shares are currently worth half of their value from 2021, facing a patent cliff that could affect $17 billion in annual revenue by 2030; while the company is pursuing new drug developments through acquisitions, it still grapples with declining COVID drug sales in the short term.
- Alexandria Real Estate's Performance: Alexandria Real Estate Equities (ARE) has seen its stock plummet nearly 75% since its 2022 peak, primarily due to rising interest rates and an oversupply of lab space; although it is leasing to tech companies to offset demand issues, it still faces ongoing financial pressures and plans to cut its dividend by 45%.
- Healthpeak Properties IPO Plans: Healthpeak Properties (DOC) is set to launch an IPO for its senior housing portfolio, which will expose it to greater market risks despite retaining a majority stake; currently, its dividend coverage is slightly above 70%, but the company must demonstrate recovery potential in the life sciences sector.
See More
- Charitable Recognition: Alexandria Real Estate has been named one of America's Most Charitable Companies, highlighting its exceptional commitment to social responsibility and enhancing its reputation among investors and the public.
- Comprehensive Evaluation: This award was developed by Newsweek in collaboration with market research partner Statista, based on an independent survey of approximately 18,000 U.S. residents that assessed companies' philanthropic activities and social impact.
- Community Support Excellence: Alexandria's outstanding support for local and community-based organizations demonstrates its active engagement in social good beyond business interests, further solidifying its leadership position in the industry.
- Brand Image Enhancement: By receiving this honor, Alexandria Real Estate not only boosts its brand image but may also attract more investor attention, potentially driving future business growth and market expansion.
See More
- Charitable Recognition: Alexandria Real Estate has been named one of America's Most Charitable Companies by Newsweek, highlighting its exceptional commitment to social responsibility and community support, which reinforces its brand as a mission-driven company.
- Innovative Medical Collaboration: The company received the Charles A. Sanders Award from the Foundation for the National Institutes of Health, recognizing its contributions to accelerating biomedical innovation, particularly in developing a precision medicine framework for depression in collaboration with the National Institute of Mental Health and the FDA.
- Market Capitalization: As of December 31, 2025, Alexandria's market capitalization reached $20.75 billion, with an asset base of 35.9 million square feet of operating properties, demonstrating its leadership and strong asset foundation in the life science real estate sector.
- Commitment to Social Responsibility: The company is dedicated to driving community health and vitality through various social responsibility initiatives, including accelerating medical innovation, supporting military personnel and their families, and improving nutrition, showcasing its proactive role in addressing significant societal challenges.
See More
- Quarterly Dividend Announcement: Alexandria Real Estate Equities declares a quarterly dividend of $0.72 per share, consistent with previous distributions, demonstrating the company's ongoing ability to maintain stable cash flows despite market challenges.
- Stable Yield: The forward yield of 5.33% reflects the company's capacity to provide relatively attractive returns to investors in the current economic environment, thereby bolstering investor confidence.
- Shareholder Rights Assurance: The dividend will be payable on April 15, with a record date of March 31 and an ex-dividend date also on March 31, ensuring shareholders receive timely returns and further solidifying their trust in the company.
- Financing Activity Update: Alexandria Real Estate also announces a $750 million senior notes offering aimed at strengthening the company's capital structure and liquidity to address market supply-demand imbalances.
See More
- Quarterly Cash Dividend: Alexandria Real Estate Equities, Inc. has declared a quarterly cash dividend of $0.72 per common share for Q1 2026, payable on April 15, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Dividend Yield: With a dividend yield of 5.2% based on the closing stock price on February 26, 2026, this attractive yield not only draws investor interest but also enhances the company's competitive position in the market.
- Financial Flexibility: The declared dividend remains consistent with the previous quarter, reflecting the company's dedication to strengthening its robust balance sheet while enhancing financial flexibility and liquidity for effective capital utilization.
- Low Payout Ratio: The dividend payout ratio stands at a favorable 33% for the quarter ended December 31, 2025, indicating a healthy balance between dividends and funds from operations, further solidifying the company's financial health.
See More









